Alexander Egle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7491209/publications.pdf

Version: 2024-02-01

204	5,089	94433	110387
papers	citations	37	64
		h-index	g-index

210	210	210	7786
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bim is a suppressor of Myc-induced mouse B cell leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6164-6169.	7.1	444
2	A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 2016, 30, 929-936.	7.2	200
3	VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood, 2004, 103, 2276-2283.	1.4	193
4	Ropeginterferon alfa-2b, a novel IFNÎ±-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood, 2015, 126, 1762-1769.	1.4	142
5	Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Research, 1997, 57, 3331-4.	0.9	134
6	Protein Kinase C-Î²-Dependent Activation of NF-Î¹B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells InÂVivo. Cancer Cell, 2013, 23, 77-92.	16.8	131
7	Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. Blood, 1997, 90, 12-20.	1.4	129
8	Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nature Reviews Clinical Oncology, 2009, 6, 405-418.	27.6	129
9	Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle, 2010, 9, 2836-2840.	2.6	116
10	Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood, 2000, 95, 610-618.	1.4	111
11	Bim and Bmf in tissue homeostasis and malignant disease. Oncogene, 2008, 27, S41-S52.	5.9	109
12	Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia, 2016, 30, 570-579.	7.2	102
13	Differential Sensitivity of CD4+ and CD8+T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia. Blood, 1998, 91, 4273-4281.	1.4	100
14	microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood, 2010, 115, 4191-4197.	1.4	99
15	Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. Genes and Development, 2010, 24, 1602-1607.	5.9	95
16	PKCÎ² is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCÎ² as a therapeutic target in chronic lymphocytic leukemia. Blood, 2009, 113, 2791-2794.	1.4	84
17	Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia, 2011, 25, 1452-1458.	7.2	83
18	Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-Î±2. European Journal of Immunology, 1996, 26, 3119-3126.	2.9	70

#	Article	IF	Citations
19	A modified scoring of the <scp>NCCN</scp>â€<scp>IPI</scp> is more accurate in the elderly and is improved by albumin and Î²₂â€microglobulin. British Journal of Haematology, 2015, 168, 239-245.	2.5	69
20	How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. Blood, 2014, 124, 2184-2189.	1.4	60
21	Azacitidine in patients with WHO-defined AML â€“ Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. Journal of Hematology and Oncology, 2013, 6, 32.	17.0	56
22	TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. OncoImmunology, 2018, 7, e1371399.	4.6	55
23	Lessons from gainâ€•and lossâ€ofâ€function models of proâ€survival Bcl2 family proteins: implications for targeted therapy. FEBS Journal, 2015, 282, 834-849.	4.7	53
24	Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer, 2011, 117, 2163-2169.	4.1	51
25	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood, 2017, 129, 383-385.	1.4	51
26	Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Annals of Hematology, 2014, 93, 459-462.	1.8	50
27	Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Annals of Oncology, 2014, 25, 171-176.	1.2	48
28	C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. British Journal of Cancer, 2014, 111, 55-60.	6.4	48
29	Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood, 2000, 95, 610-8.	1.4	46
30	Analysis of Bcl-2 Protein Expression in Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2000, 113, 219-229.	0.7	44
31	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with pegâ€prolineâ€interferon alphaâ€2b. American Journal of Hematology, 2015, 90, 288-294.	4.1	44
32	Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells. PLoS ONE, 2011, 6, e23758.	2.5	43
33	Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood, 1997, 90, 12-20.	1.4	43
34	Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology,the, 2016, 3, e317-e329.	4.6	42
35	Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria. Infection, 2011, 39, 341-352.	4.7	40
36	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia, 2021, 35, 3059-3072.	7.2	40

#	Article	IF	Citations
37	Expression of Apoâ€1/Fas (CD95), Bclâ€2, Bax and Bclâ€x in myeloma cell lines: relationship between responsiveness to antiâ€Fas mab and p53 functional status. British Journal of Haematology, 1997, 97, 418-428.	2.5	39
38	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood, 2018, 131, 1206-1218.	1.4	39
39	Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma. Future Oncology, 2019, 15, 109-120.	2.4	39
40	Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the <scp>TCL</scp>1 transgenic mouse model. British Journal of Haematology, 2015, 170, 515-522.	2.5	38
41	Bclâ€2 proteins in development, health, and disease of the hematopoietic system. FEBS Journal, 2016, 283, 2779-2810.	4.7	37
42	Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia, 2017, 31, 1117-1122.	7.2	36
43	The interleukin 1Î²-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. FEBS Letters, 1997, 402, 36-40.	2.8	35
44	Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica, 2014, 99, 67-69.	3.5	35
45	Myocardial injury in severe COVIDâ€19 is similar to pneumonias of other origin: results from a multicentre study. ESC Heart Failure, 2021, 8, 37-46.	3.1	35
46	Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget, 2016, 7, 51494-51502.	1.8	35
47	Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood, 1998, 91, 4273-81.	1.4	35
48	Viral infections and their management in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1602-1613.	1.3	32
49	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematology,the, 2021, 8, e135-e148.	4.6	32
50	Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood, 2006, 108, 2950-2956.	1.4	31
51	Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunology, Immunotherapy, 2011, 60, 75-85.	4.2	31
52	Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. Leukemia, 2014, 28, 954-958.	7.2	29
53	The significance of pretreatment anemia in the era of Râ€<scp>IPI</scp> and <scp>NCCN</scp>â€<scp>IPI</scp> prognostic risk assessment tools: a dualâ€center study in diffuse large Bâ€cell lymphoma patients. European Journal of Haematology, 2015, 95, 538-544.	2.2	29
54	B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance. International Journal of Cancer, 1991, 47, 870-874.	5.1	28

#	Article	IF	Citations
55	On the Role and Significance of Fas (Apo-1/CD95) Ligand (FasL) Expression in Immune Privileged Tissues and Cancer Cells Using Multiple Myeloma as a Model*. Leukemia and Lymphoma, 1998, 31, 477-490.	1.3	28
56	Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1501-1508.	4.9	28
57	DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer. Theranostics, 2018, 8, 2278-2288.	10.0	28
58	NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. British Journal of Cancer, 2016, 115, 1264-1272.	6.4	27
59	Raltegravir in pregnancy: a case series presentation. International Journal of STD and AIDS, 2011, 22, 358-360.	1.1	26
60	Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 469-477.	1.1	26
61	Clonal evolution and heterogeneity in metastatic head and neck cancerâ€"An analysis of the Austrian Study Group of Medical Tumour Therapy study group. European Journal of Cancer, 2018, 93, 69-78.	2.8	25
62	Mimicking the microenvironment in chronic lymphocytic leukaemia â€“ where does the journey go?. British Journal of Haematology, 2013, 160, 711-714.	2.5	24
63	Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?. Journal of Thrombosis and Thrombolysis, 2021, 51, 226-231.	2.1	24
64	Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. , 1996, 65, 498-505.		23
65	BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-ÎºB Nuclear Translocation. Clinical Cancer Research, 2019, 25, 1901-1912.	7.0	23
66	2â€²,2â€²â€Ðifluorodeoxycytidine (Gemcitabine) Induces Apoptosis in Myeloma Cell Lines Resistant to Steroids and 2â€€hlorodeoxyadenosine (2â€€dA). Stem Cells, 1996, 14, 351-362.	3.2	22
67	Update on squamous cell carcinoma of the head and neck. Memo - Magazine of European Medical Oncology, 2017, 10, 220-223.	0.5	22
68	Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Leukemia, 2019, 33, 957-968.	7.2	22
69	TNF cytokine family: More BAFF-ling complexities. Current Biology, 2001, 11, R1013-R1016.	3.9	21
70	Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia, 2012, 26, 2508-2516.	7.2	21
71	Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Research, 1991, 51, 5821-5.	0.9	21
72	Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. BMC Complementary and Alternative Medicine, 2014, 14, 115.	3.7	20

#	Article	IF	Citations
73	The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. Pharmacogenomics Journal, 2018, 18, 474-479.	2.0	20
74	Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. Blood, 1997, 90, 12-20.	1.4	20
75	Protein Kinase C-Î² Dependent Activation of NF-Î°B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B-Cells in Vivo. Blood, 2012, 120, 314-314.	1.4	20
76	Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. Blood, 2018, 131, 1337-1349.	1.4	18
77	Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCLâ€2 and/or BIM. European Journal of Haematology, 2019, 102, 437-441.	2.2	18
78	Stromal cell protein kinase C-Î² inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. Science Translational Medicine, 2020, 12, .	12.4	18
79	CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. Oncotarget, 2015, 6, 12048-12060.	1.8	18
80	B-cellâ€“specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. Blood, 2019, 134, 1717-1729.	1.4	17
81	Ixazomibâ€“Thalidomideâ€“Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. British Journal of Cancer, 2019, 121, 751-757.	6.4	17
82	RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. Leukemia, 2021, 35, 1053-1063.	7.2	17
83	Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study. Blood, 2008, 112, 3175-3175.	1.4	17
84	A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study. Open Forum Infectious Diseases, 2016, 3, ofw089.	0.9	16
85	The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. Journal of Clinical Pathology, 2016, 69, 326-330.	2.0	15
86	CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model. Leukemia, 2016, 30, 1409-1413.	7.2	15
87	Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine â€“ A retrospective single center experience. Leukemia Research, 2017, 59, 12-19.	0.8	15
88	Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. PLoS ONE, 2017, 12, e0180995.	2.5	15
89	The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Frontiers in Oncology, 2020, 10, 609409.	2.8	15
90	Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. Antiviral Therapy, 2009, 14, 1189-1193.	1.0	14

#	Article	IF	Citations
91	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leukemia and Lymphoma, 2020, 61, 377-386.	1.3	14
92	Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. British Journal of Haematology, 1998, 102, 1069-1080.	2.5	13
93	ILK Induction in Lymphoid Organs by a TNFÎ±â€“NF-ÎºBâ€“Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia. Cancer Research, 2016, 76, 2186-2196.	0.9	13
94	CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. BMC Cancer, 2015, 15, 725.	2.6	12
95	Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. PLoS ONE, 2018, 13, e0206688.	2.5	12
96	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30â€positive aggressive lymphomas. European Journal of Haematology, 2020, 104, 251-258.	2.2	12
97	Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera â€" Final Phase I/II Peginvera Study Results. Blood, 2018, 132, 3030-3030.	1.4	12
98	Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level. PLoS ONE, 2013, 8, e74024.	2.5	12
99	Expression Levels of CD38 in Tumor Cells and T-Cells Are of Prognostic Value in B-CLL.. Blood, 2005, 106, 1189-1189.	1.4	12
100	B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia. Haematologica, 2015, 100, e307-10.	3.5	10
101	C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. Journal of Clinical Medicine, 2019, 8, 1791.	2.4	9
102	The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis.. Blood, 2009, 114, 3453-3453.	1.4	9
103	Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. BMC Cancer, 2015, 15, 996.	2.6	8
104	The AKT 1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. British Journal of Haematology, 2016, 172, 815-819.	2.5	8
105	Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results. Blood, 2013, 122, 4164-4164.	1.4	8
106	Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial. Blood, 2014, 124, 20-20.	1.4	8
107	CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. Oncotarget, 2016, 7, 49459-49469.	1.8	8
108	Evaluation of circulating cellâ€free DNA as a molecular monitoring tool in patients with metastatic cancer. Oncology Letters, 2020, 19, 1551-1558.	1.8	8

#	Article	IF	Citations
109	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. Lancet Infectious Diseases, The, 2022, 22, 764-765.	9.1	8
110	Kasabachâ€Merritt phenomenon in hepatic angiosarcoma. British Journal of Haematology, 2014, 167, 716-718.	2.5	7
111	Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLLâ€8a mabtenance trial. Cancer Medicine, 2019, 8, 1401-1405.	2.8	7
112	Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. Journal of Clinical Medicine, 2020, 9, 1663.	2.4	7
113	A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results. Blood, 2011, 118, 292-292.	1.4	7
114	Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial. Annals of Hematology, 2017, 96, 1155-1162.	1.8	6
115	Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Annals of Hematology, 2018, 97, 1825-1839.	1.8	6
116	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. Supportive Care in Cancer, 2021, 29, 5197-5207.	2.2	6
117	Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. Pancreatology, 2021, 21, 1466-1471.	1.1	6
118	Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study. Blood, 2013, 122, 4046-4046.	1.4	6
119	The SpiegelmerÂ® Nox-A12 Abrogates Homing Of Human CLL Cells To Bone Marrow and Mobilizes Murine CLL Cells In The Eî¼-TCL1 Transgenic Mouse Model Of CLL. Blood, 2013, 122, 4111-4111.	1.4	6
120	IL-10 serum levels in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 1996, 94, 211-2.	2.5	6
121	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. ESMO Open, 2021, 6, 100012.	4.5	5
122	AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL. Cancers, 2021, 13, 2619.	3.7	5
123	Deletion of Puma and p21Waf1 In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence. Blood, 2010, 116, 90-90.	1.4	5
124	Protein kinase C-Î²-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia. Stem Cells, 2021, 39, 819-830.	3.2	5
125	An uncommon cause of anaemia: Sheehan's syndrome. Wiener Klinische Wochenschrift, 2010, 122, 717-719.	1.9	4
126	Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping. Journal of Clinical Oncology, 2016, 34, 2433-2434.	1.6	4

#	Article	IF	Citations
127	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. Cancers, 2021, 13, 650.	3.7	4
128	Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone. Wiener Klinische Wochenschrift, 2021, 133, 1131-1136.	1.9	4
129	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2) Tj ETQq1 1 0.784314 rgBT /Overl Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02). Blood, 2019, 134, 696-696.	1.4	4
130	AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV). Blood, 2012, 120, 175-175.	1.4	4
131	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agentsâ€"A Prospective Cohort Study of the AGMT Study-Group. Cancers, 2022, 14, 2459.	3.7	4
132	Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient. Annals of Hematology, 2013, 92, 1001-1002.	1.8	3
133	Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. Leukemia and Lymphoma, 2015, 56, 353-360.	1.3	3
134	Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia. Wiener Klinische Wochenschrift, 2017, 129, 141-144.	1.9	3
135	Reduced alpha diversity of the oral microbiome correlates with short progressionâ€free survival in patients with relapsed/refractory multiple myeloma treated with ixazomibâ€based therapy (AGMT MM 1,) Tj ETQq1 1 0.784314 rgBT /O	3	
136	Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburgâ€"a report from the AGMT COVID-19 Registry. GeroScience, 2021, 43, 1877-1897.	4.6	3
137	Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy. International Journal of Molecular Sciences, 2021, 22, 5449.	4.1	3
138	The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms. International Journal of Molecular Sciences, 2021, 22, 9555.	4.1	3
139	Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity. PLoS ONE, 2012, 7, e30667.	2.5	3
140	A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort Study. International Journal of Environmental Research and Public Health, 2021, 18, 12532.	2.6	3
141	The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial. Haematologica, 2006, 91, 1291-3.	3.5	3
142	Human immunodeficiency virus type 2 infections in Austria. Wiener Klinische Wochenschrift, 2014, 126, 212-216.	1.9	2
143	Remission maintenance treatment options in chronic lymphocytic leukemia. Cancer Treatment Reviews, 2018, 70, 56-66.	7.7	2
144	TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. Leukemia, 2020, 34, 2498-2502.	7.2	2

#	Article	IF	Citations
145	A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report. International Journal of Molecular Sciences, 2021, 22, 9410.	4.1	2
146	Planned First Safety and Efficacy Analysis of Oral Fludarabine Combined with Subcutaneous Alemtuzumab in 2nd Line Therapy of B-Chronic Lymphocytic Leukaemia (B-CLL): The FLUSALEM Study.. Blood, 2006, 108, 4990-4990.	1.4	2
147	The BENDALEM CLL 6 AGMT Study â€“ Bendamustine Combined with Alemtuzumab In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis. Blood, 2010, 116, 4633-4633.	1.4	2
148	Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. Blood, 2011, 118, 1715-1715.	1.4	2
149	Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient. Blood, 2012, 120, 1613-1613.	1.4	2
150	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. Blood, 2014, 124, 1976-1976.	1.4	2
151	Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group. Blood, 2019, 134, 3821-3821.	1.4	2
152	Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry. Blood, 2021, 138, 3387-3387.	1.4	2
153	Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights. Discovery Medicine, 2009, 8, 157-64.	0.5	2
154	Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19. Antimicrobial Resistance and Infection Control, 2021, 10, 170.	4.1	2
155	Riding the 2-edged sword. Blood, 2010, 115, 4325-4326.	1.4	1
156	MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer. Journal of Nucleic Acids Investigation, 2010, 1, 14.	0.8	1
157	3.22 Diversity of T-Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S212.	0.4	1
158	Complete Remission of WaldenstrÃ¶m Macroglobulinemia With Azacitidine and Rituximab. Journal of Clinical Oncology, 2011, 29, e696-e698.	1.6	1
159	Whatâ€™s new in Hodgkinâ€™s lymphoma: ASH 2012 and more. Memo - Magazine of European Medical Oncology, 2013, 6, 193-196.	0.5	1
160	Bid-ding for mercy: twisted killer in action. Cell Death and Differentiation, 2013, 20, 847-849.	11.2	1
161	Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome. Oncology Letters, 2013, 6, 1756-1758.	1.8	1
162	Old and new news in CLL: â€œltâ€™s the pathway, stupid!â€• Blood, 2014, 124, 989-990.	1.4	1

#	Article	IF	Citations
163	Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia. Memo - Magazine of European Medical Oncology, 2015, 8, 38-42.	0.5	1
164	An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer. Annals of Oncology, 2016, 27, vi231.	1.2	1
165	UNMAINTAINED REMISSION AFTER DISCONTINUATION OF KINASE INHIBITOR TREATEMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: AN OBSERVATIONAL COHORT. Hematological Oncology, 2019, 37, 218-219.	1.7	1
166	Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study. Blood, 2010, 116, 1380-1380.	1.4	1
167	Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud. Blood, 2015, 126, 1603-1603.	1.4	1
168	Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study. Blood, 2011, 118, 1747-1747.	1.4	1
169	The role of maintenance strategies in lymphoma and CLL. Memo - Magazine of European Medical Oncology, 2013, 6, 102-108.	0.5	0
170	Therapy with JAK 1/2 inhibitors for myelofibrosis. Memo - Magazine of European Medical Oncology, 2013, 6, 109-113.	0.5	0
171	Pleural decortication of a marginal zone lymphoma. Annals of Hematology, 2014, 93, 1253-1254.	1.8	0
172	Milestones inÂChronic Lymphocytic Leukemia. Memo - Magazine of European Medical Oncology, 2017, 10, 8-12.	0.5	0
173	Establishment and validation of aÂnovel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener Klinische Wochenschrift, 2018, 130, 115-125.	1.9	0
174	Interdisciplinary Model for Scheduling Post-discharge Cardiopulmonary Care of Patients Following Severe and Critical SARS-CoV-2 (Coronavirus) Infection. Frontiers in Cardiovascular Medicine, 2020, 7, 157.	2.4	0
175	Planned First Efficacy and Safety Analysis of De-Intensified Induction with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos Study.. Blood, 2007, 110, 2045-2045.	1.4	0
176	T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcl1 Transgenic Chronic Lymphocytic Leukemia Model. Blood, 2008, 112, 3145-3145.	1.4	0
177	The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia.. Blood, 2009, 114, 1238-1238.	1.4	0
178	Report on Response and Overall Survival of 128 Unselected, Consecutive AML Patients From the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. Blood, 2011, 118, 4266-4266.	1.4	0
179	Azacitidine Is Feasible and Safe in Patients with MDS and Co-Existing Plasma Cell Dysplasias (PCD) - Report on 9 Patients From the Austrian Azacitidine Registry (AAR). Blood, 2011, 118, 5056-5056.	1.4	0
180	Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia. Blood, 2011, 118, 803-803.	1.4	0

#	Article	IF	Citations
181	KCa3.1 Blockers Inhibit Cell Proliferation in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3887-3887.	1.4	0
182	T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia. Blood, 2012, 120, 1773-1773.	1.4	0
183	BIRC3 but Not BIRC2 mRNA Expression in Chronic Lymphocytic Leukemia Correlates with Disease Progression and Mediates Decreased Fludarabine Sensitivity in Vitro. Blood, 2012, 120, 563-563.	1.4	0
184	Chronic Lymphocytic Leukemia Cells With Trisomy 12 Home To The Bone Marrow In a CXCR4-Independent Manner and Are Prone To Proliferate In Vitro. Blood, 2013, 122, 870-870.	1.4	0
185	Proteinkinase C-Î² Inhibitors Mitigate Microenvironment-Mediated Survival Of CLL Cells and Sensitise Malignant B Cells To Cytotoxic Drugs. Blood, 2013, 122, 669-669.	1.4	0
186	Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model. Blood, 2014, 124, 3298-3298.	1.4	0
187	The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner. Blood, 2014, 124, 1973-1973.	1.4	0
188	Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study. Blood, 2014, 124, 3177-3177.	1.4	0
189	Spliceosome Mediated RNA Trans-Splicing for Targeting Kappa+ B-Cell Neoplasms. Blood, 2014, 124, 3633-3633.	1.4	0
190	Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Blood, 2014, 124, 77-77.	1.4	0
191	Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient. Blood, 2015, 126, 4056-4056.	1.4	0
192	Time-to-Treatment in Chronic Myelomonocytic Leukemia - a Novel Prediction Model. Blood, 2016, 128, 5547-5547.	1.4	0
193	Deletion of the p53 Target Gene PUMA Prevents Bone Marrow Failure in a Dyskeratosis Congenita Mouse Model. Blood, 2018, 132, 648-648.	1.4	0
194	Abstract P3-10-07: A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. , 2019, , .		0
195	BCR-Induced VLA-4 Activation in the TCL1 Transgenic Mouse Model for Chronic Lymphocytic Leukemia. Blood, 2019, 134, 1730-1730.	1.4	0
196	Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry. Blood, 2021, 138, 1130-1130.	1.4	0
197	The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group. Blood, 2021, 138, 64-64.	1.4	0
198	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study). Blood, 2021, 138, 1669-1669.	1.4	0

#	Article	IF	Citations
199	Lack of Bmf Facilitates the Selection of Highly Responsive B-Cell Receptor Clones in Chronic Lymphocytic Leukemia. Blood, 2021, 138, 1543-1543.	1.4	0
200	Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study). Blood, 2020, 136, 29-30.	1.4	0
201	Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). Blood, 2020, 136, 27-29.	1.4	0
202	The Integrin Adaptor Kindlin-3 Is Important for Development and Retention of Marginal Zone B Cells. Blood, 2020, 136, 46-47.	1.4	0
203	Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study. Blood, 2020, 136, 26-26.	1.4	0
204	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	2.1	0